Introduction
Estimation of whole-body insulin sensitivity and action with the euglycemic clamp technique is mainly a reflection of the glucose disposal by the muscles (60 -70%). 1 The adipose tissue only accounts for $ 10% of the insulin-stimulated whole body glucose uptake and the liver for $ 30%. Thus, an impaired insulin-stimulated glucose disposal during a euglycemic clamp is mainly due to a reduced glucose uptake by the muscles. This fact has led to the extrapolation that whole body insulin resistance not only occurs in, but also starts in, the muscles. This is an unwarranted extrapolation, which may lead us wrong in the search for pathogenetic mechanisms.
Animal models, both transgenic overexpressing and gene 'knock-outs', have provided us with exciting insights into the phenotypic consequences of specific gene overexpression or ablation. Gene ablation of the important docking proteins IRS-1 and IRS-2 have produced growth-retarded and markedly insulin-resistant (IRS-1) 2 or insulin-resistant and diabetic animals with an impaired insulin secretion (IRS-2). 3 Muscle-specific GLUT4 ablation leads to insulin resistance, 4 but so does adipose-specific GLUT4 gene knock-out, in fact to what appears to be a similar degree. 5 This finding is obviously not congruent with an unimportant role of the adipose tissue for whole-body glucose disposal. Another interesting finding in the animal models is that muscle GLUT4 depletion is associated with a marked increase in glucose uptake by the fat and with an expanded adipose tissue mass. 6 This cross-talk between tissues supports the possibility that insulin resistance may be initiated in one tissue which then is followed by a series of events in other tissues=organs.
This brief overview summarizes our recent findings in human subjects showing that insulin resistance and an impaired insulin effect occur early in the adipose tissue; in fact, long before glucose intolerance develops. It is then speculated that the adipose tissue may initiate and=or be the initial target organ for insulin where insulin resistance develops. Recent data where insulin signaling and action have been studied in the target tissues in man in insulinresistant states, in particular in type 2 diabetes, will be reviewed. Since virtually nothing is known about insulin signaling downstream of the insulin receptor in human liver, comparisons can only be made between skeletal muscle and adipose cells.
Type 2 diabetes
The effect of insulin, either infused in vivo or added in vitro, on glucose transport and insulin signaling in skeletal muscle from type 2 diabetic subjects has been recently reviewed. 7 The salient findings are an impaired insulin-stimulated tyrosine phosphorylation of IRS-1, associated with $ 50% reduction in PI3-kinase activity. However, the downstream activation of the important serine=threonine kinase PKB=Akt appears to be normal 8 or only impaired in the presence of a supraphysiological insulin concentration added in vitro. 9 The impaired tyrosine phosphorylation does not appear to be due to a reduced IRS-1 protein expression, although lower levels have been seen in some cells in gestational diabetes. 10 An increased serine phosphorylation of IRS-1 may reduce the insulin-stimulated tyrosine phosphorylation, 11 but it is currently unknown whether this is the case in type 2 diabetes. Taken together, the data suggest that the activation of PI3-kinase, and presumably the generation of PI3, 4-and PI3, 4, 5 phosphates, is reduced but still sufficient to allow a normal activation of the downstream signaling events. This has led to the conclusion that insulin resistance in skeletal muscle is caused by an impaired activation of effector or signaling molecules downstream of PKB=Akt. 8 Insulin-stimulated glucose transport is also reduced in skeletal muscle from type 2 diabetic subjects.
12 Surprisingly, however, recent in vitro studies have shown that this appears to be mainly caused by a 'glucose toxicity'. Preincubating the tissue biopsies for only 2 h at a high glucose concentration impairs the effect of insulin, 13 while preincubating diabetic muscle strips for 2 h at a physiological glucose concentration normalizes the insulin response. 13 However, it is also possible that the preincubation period overcomes the effect of other circulating antagonists to insulin action such as TNFa, the interleukins and=or free fatty acids (FFA). 14, 15 Taken together, currently available data suggest that there are only modest, and obviously not functionally critical, impairments in insulin signaling upstream of PKB=Akt in skeletal muscle from type 2 diabetic subjects. Furthermore, the impaired insulin-stimulated glucose transport appears to be rapidly reversible in vitro by preincubating the tissue samples in fresh medium containing a physiological glucose concentration. These findings are also in agreement with the consistent demonstration that both the GLUT4 protein content and mRNA expression are normal in skeletal muscle in type 2 diabetes. 7, 16 The situation is quite different in the adipose tissue. Adipocytes from type 2 diabetic subjects also have a marked reduction in the insulin-stimulated tyrosine phosphorylation of IRS-1. However, this is mainly due to a $ 70% reduction in IRS-1 protein expression. 17 Similarly, total PI3-kinase activity is reduced $ 70%. In contrast, IRS-2 expression is normal and this molecule also becomes the main docking protein for insulin-stimulated PI3-kinase activation. 17 In agreement with the reduced PI3-kinase activation, the downstream activation of PKB=Akt is also markedly impaired, mainly due to a major reduction in the insulinstimulated serine phosphorylation. 18 Glucose transport in response to insulin is also reduced in fat cells from type 2 diabetic subjects due to both the impaired insulin signaling as well as a marked reduction ( $ 70 -80%) in GLUT4 protein and mRNA expression. 17, 19, 20 In contrast to muscle cells as discussed above, preincubating human fat cells for 16 h at physiological (5.6 mmol=l) or high glucose concentrations (16.8 and 25 mmol=l) does not impair the acute stimulatory effect of insulin on glucose uptake ( Figure 1 ) nor does preincubation of diabetic cells at a physiological glucose concentration restore the acute insulin response after 6 h (unpublished observations). This is consistent with the reduced GLUT4 protein expression in adipocytes which probably requires a longer time for reversal. Table 1 summarizes the salient differences in the upstream insulin-stimulated events in muscle and fat from individuals with type 2 diabetes compared to non-diabetic subjects.
Normoglycemic, insulin-resistant states
Studies with skeletal muscle from non-diabetic relatives to type 2 diabetic subjects have shown that both insulin-stimulated glucose uptake and glycogen synthesis are reduced. 7, 20 Some defects in insulin signaling have been reported and they appear to be similar to those seen in type 2 diabetes. These perturbations include a modest reduction in insulin receptor phosphorylation and tyrosine kinase activity, 21 in insulin-stimulated IRS-1 tyrosine phosphorylation 22, 23 and PI3-kinase activity. 22 -24 However, IRS-1 protein expression appears to be unchanged, 22 -24 but a small ( $ 30%) reduction in IRS-1 protein expression was reported in morbidly obese subjects. 25 Insulin-stimulated downstream activation of PKB=Akt appears to be normal or only moderately decreased. 22, 23 Cultured skeletal muscle from insulinsensitive and -resistant subjects showed no impairments Insulin resistance in adipocytes U Smith in the ability of insulin to increase the receptor tyrosine kinase activity, IRS-1-associated PI3-kinase activity or serine phosphorylation (ie activation) of PKB=Akt. 26 In contrast, an impaired glucose transport and glycogen production in response to insulin have been documented in cultured skeletal muscle cells from non-diabetic insulin-resistant subjects. 27 Taken together, although insulin-stimulated glucose transport and glycogen synthesis are reduced in skeletal muscle from both diabetic and non-diabetic, insulinresistant subjects, only modest defects have been found in the intracellular signaling events. These findings are also in agreement with the modest upstream impairments in insulin signaling in type 2 diabetes as discussed above.
In contrast, we have recently found that a cohort of healthy subjects, particularly in those with a marked genetic predisposition for type 2 diabetes (two first-degree relatives with the disease), exhibit similar abnormalities in insulin signaling in the adipocytes as those seen in diabetic cells. 28, 29 Thus, IRS-1 expression was reduced $ 70% (Figure 2) , and insulin-stimulated PI3-kinase activity and PKB=Akt serine phosphorylation and activity were similarly reduced. 29 Interestingly, insulin-stimulated glucose transport and GLUT4 expression were also reduced to a similar extent as in diabetic cells. 29 These abnormalities were seen in $ 30% of individuals with a marked genetic predisposition for type 2 diabetes but only in $ 5% of the subjects with no known diabetes heredity. We also found similar abnormalities in some morbidly obese subjects ( Figure 2) . 28 Unfortunately, no information was available on diabetes heredity in this group. However, since diabetes heredity by itself is associated with a higher body weight and obesity, 30 -32 as well as an increased weight gain in prospective studies, 31 it is feasible that the obese individuals with low IRS-1 expression in the fat cells also had a genetic predisposition for type 2 diabetes. We found no association between a low IRS-1 expression and the common Arg972 Gly polymorphism of the IRS-1 gene. 28 Thus, both low IRS-1 and GLUT4 gene and protein expression are seen in fat cells from type 2 diabetic subjects as well as in a group of healthy individuals, mainly those with a marked heredity for type 2 diabetes. The downstream signaling events for insulin are also similarly impaired in these groups. The healthy individuals with these cellular abnormalities are also markedly insulin resistant in vivo, have higher fasting insulin and triglyceride levels, thus exhibiting several signs of the Insulin Resistance (or Metabolic) Syndrome. 33 Furthermore, the fact that these individuals were resistant to the ability of insulin to stimulate glucose uptake in vivo Insulin resistance in adipocytes U Smith during a euglycemic clamp shows that muscle uptake was reduced, probably due to an impaired glucose transport. 34 It is unlikely that the molecular abnormalities seen in the adipose cells are secondary to the insulin resistance and hyperinsulinemia. Although IRS-1 protein can be reduced by prolonged and marked hyperinsulinemia in vitro, 35 many obese subjects had both hyperinsulinemia and normal IRS-1 expression. Furthermore, the reduced GLUT4 expression cannot be explained by this possibility.
As discussed above, the major consistent finding in muscle in type 2 diabetes seems to be an impairment (rapidly reversible?) in insulin-stimulated glucose transport and glycogen synthesis, while PKB=Akt activation is normal. Although this does not exclude major abnormalities in other, still undefined, molecular targets of insulin action in muscle like c-Cbl-associated protein (CAP), 36 it is also clear that there are major differences in this regard between fat and muscle. Thus, a low IRS-1 expression in the adipocytes is a biomarker of insulin resistance and propensity for type 2 diabetes. 28 A key question, then, is why there are these differences in insulin signaling and gene and protein expression between two major target tissues for insulin. Although there are no firm answers to this, one possibility is that the adipose tissue initiates and=or is the initial tissue where insulin resistance develops. This could then lead to a series of events whereby insulin resistance is induced or augmented in muscle and liver.
One possibility is that the reduced IRS-1 and GLUT4 expression in the fat cells by itself leads to a reduced whole-body insulin sensitivity. As discussed above, a reduction in the relatively small glucose uptake by the adipose tissue ( $ 10%) is unlikely to lead to a marked insulin resistance in vivo. However, by the same token, specific GLUT4 deletion in the adipose tissue produced animals with a marked insulin resistance. 5 Interestingly, both the liver and skeletal muscle were insulin resistant in vivo while insulinstimulated glucose uptake was normal in skeletal muscle in vitro. 5 This discrepancy suggests that circulating antagonists, possibly induced by a low glucose uptake in the adipose tissue, accounted for the insulin resistance in liver and muscle in vivo. Since there were no differences in circulating FFA levels between the wild-type and GLUT4-depleted animals, 5 other possibilities have to be considered. The endocrine function of the adipose tissue provides a possible explanation to this discrepancy through, for instance, an increased production of cytokines like TNFa, IL-6 or resistin. Interestingly, experimental studies in 3T3-L1 cells have shown that chronic exposure to TNFa reduces both IRS-1 and GLUT4 expression. 37 Similarly, we have recently found that IL-6 is capable of producing the same effects (Rotter et al, submitted for publication). Thus, low IRS-1 and GLUT4 may be markers of and=or lead to an excessive production of IL-6 and=or TNFa or other cytokines or hormones, which both reduce the expression of these proteins in the adipocytes in an autocrine or paracrine fashion as well as inducing insulin resistance in muscles and, possibly, the liver. In addition, cytokines like TNFa have been found to markedly increase lipolysis and FFA release, at least in part through a reduced perilipin expression 38 and decreased Gi protein expression, 39 further augmenting the impaired cellular insulin signaling and glucose uptake. 15 Recently, the adipose tissue was found to secrete another peptide, resistin, 40 which may be related to the insulin resistance in obesity. A similar protein, called FIZZ1 41 was previously isolated from inflammatory cells in pulmonary lavage from animals with experimentally induced asthma. However, the overall role of resistin in insulin resistance in man is conjectural. Two recent studies were unable to detect resistin expression in human fat cells 42, 43 irrespective of degree of obesity 42 or insulin resistance. 43 An additional possibility is that low IRS-1 and GLUT4 expression in the fat cells is associated with elevated lipolysis and circulating FFA levels which, in turn, impair insulin action in vivo. 15 However, fasting FFA levels are not different in these subjects when compared to carefully matched individuals with a normal expression of these proteins but the ability of insulin to lower the FFA levels is, as expected, impaired.
Although there is much evidence to support an endocrine cross-talk between fat and muscle (and liver?), it is currently unclear how such a mechanism can explain the fact that lipoatrophy is also associated with insulin resistance and diabetes. In one animal model of lipoatrophy, it was found that the insulin resistance was probably due to lack of leptin. 44 Administering leptin to these animals markedly improved insulin sensitivity, possibly due to an increased oxidation of the excessively accumulated lipids in muscle and other tissues. 45 In contrast, in another animal model of total lipoatrophy, leptin was unable to improve the insulin resistance but transplantation of fat led to a marked improvement. 46 Thus, the adipose tissue not only produces peptides which can elicit insulin resistance but also hormones which can improve insulin resistance such as leptin 45 and adiponectin. 47 -49 Circulating adiponectin levels are positively correlated to insulin sensitivity and negatively related to BMI. 48 Furthermore, administration of adiponectin to animal models of insulin resistance and diabetes improves insulin sensitivity. 49 Thus, it is likely that the balance of the production of hormones from the adipose tissue that accentuate (like IL-6 and TNFa) or alleviate (like leptin and adiponectin) insulin resistance, as well as eliciting other effects, is due to several factors including adipose mass, nutritional state and genetic background.
Effects of thiazolidinediones on IRS-1 and IRS-2 expression
Thiazolidinediones (TZD), the novel insulin sensitizers used in the treatment of type 2 diabetes, are ligands for PPARg which is predominantly expressed in the adipose tissue. 50 Insulin resistance in adipocytes U Smith
Support for the pivotal role of the adipose tissue for the insulin-sensitizing effect of TZD comes from the recent work of Gavrilova et al. 46 These authors found that TZDs lost their beneficial effect on insulin sensitivity in totally lipoathropic mice while the lipid-lowering (probably PPARa) effect remained. Thus, an interesting question for us was to examine whether TZD could restore or increase the expression of IRS-1 in the fat cells. We addressed this by using both differentiated 3T3-L1 adipocytes as well as human adipose tissue in culture with or without the addition of different PPAR-ligands. However, we found no evidence that IRS-1 was a target for TZD but, interestingly, the IRS-2 gene was clearly activated by PPARg but not PPARa ligands. 51 IRS-2 mRNA was rapidly increased (within 4 h) and remained elevated over the observation period of 48 h. Furthermore, IRS-2 protein was markedly increased. 51 Thus, these data show that TZD increase IRS-2 gene and protein expression and suggest that this may be one mechanism for the insulin sensitizing effect of these drugs. This possibility is further supported by our recent finding that IRS-2 expression was also increased by pioglitazone in cultured human fat cells from type 2 diabetic (and, thus, having low IRS-1 expression) individuals (Figure 3) . IRS-2 is the main docking protein for PI3-kinase activation in fat cells when IRS-1 is markedly reduced, such as in type 2 diabetes, 17 as discussed above. Similarly, IRS-2 functions as a major docking protein in cells from IRS-1 'knock-out' animals. 52 In addition, IRS-2 appears to be the predominant IRSmolecule expressed in liver and b-cells 3, 53 and abnormalities in these organs also appear to be a major cause of the 'type 2' diabetes in IRS-2 'knock-out' animals. 54 We have recently examined cellular IRS-2 levels in ob=ob animals treated for 6 Insulin resistance in adipocytes U Smith days with TZD and also find an increased expression in fat cells (unpublished observation). However, it is currently unclear if TZD also increase IRS-2 expression in muscle, liver and b-cells but this is the subject of an ongoing study.
An increased IRS-2 expression in fat, liver and=or muscle could substitute for the reduced IRS-1 protein and=or the impaired phosphorylation and activation by insulin, leading to an increased insulin sensitivity. Furthermore, a putative increase in IRS-2 expression in b-cells by TZD may be important for both growth and function. 55 However, it would seem an attractive therapeutic possibility to have agents which directly increase IRS-1 expression since this docking protein is the major activator of PI3-kinase in response to insulin in human fat cells and, in contrast to IRS-2, is markedly reduced in adipocytes in insulin-resistant states. We here suggest that the tissue-specific reduction in gene and protein expression of IRS-1 and GLUT4 may play an important role in the development of the whole-body insulin resistance either directly or indirectly by an association with an increased production of cytokines and=or other insulin-antagonistic factors ( Figure 4 ). TZD may alleviate or normalize this effect by increasing IRS-2 expression in fat cells and, possibly, also other target tissues for insulin and the pancreatic b-cells.
Although this review is focused on recent findings relating insulin resistance to an early impaired insulin signaling and action in fat cells through a reduced IRS-1=GLUT4 expression, and the effect of TZD on IRS-1=IRS-2, TZD clearly also elicit other important changes in the adipose tissue. These include the recruitment of new and smaller fat cells through an increased adipogenesis, a process where both IRS-1 and IRS-2 play a critical role, 56 altered expression of genes directly or indirectly related to insulin action, 57 including an inhibition of cytokine release by the fat cells. 57, 58 In addition, the ability of TNFa to stimulate lipolysis and FFA release is also antagonized by TZD. 38 However, insulin is a key regulator of lipolysis and circulating FFA levels in vivo and the antilipolytic effect of insulin is mediated through the activation of PI3-kinase. 59 Thus, a reduced IRS-1 expression and insulin-stimulated PI3-kinase activity will also link insulin resistance, as defined by a reduced insulin-stimulated glucose uptake, to an impaired ability of insulin to suppress lipolysis.
